Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.83 |
| ▸ | PTGS1 | P23219 | 10/20 | 0.83 |
| ▸ | PDPK1 | O15530 | 5/20 | 0.71 |
| ▸ | PTGES | O14684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3246957 | 0.91 | PTGS2 (1.00) | PTGS2PTGS1PDPK1PTGESCYP2C9 | |
| SCHEMBL6339309 | 0.88 | PDPK1 (0.83) | PTGS2PTGS1PDPK1PTGES | |
| SCHEMBL6013920 | 0.88 | PTGS2 (0.78) | PTGS2PTGS1PDPK1PTGESCYP2C9 | |
| SCHEMBL3244766 | 0.87 | PTGS2 (1.00) | PTGS2PTGS1PDPK1 | |
| SCHEMBL6013952 | 0.86 | PTGS2 (0.80) | PTGS2PTGS1PDPK1PTGESCYP2C9 | |
| SCHEMBL6353412 | 0.86 | PTGS2 (0.76) | PTGS2PTGS1PDPK1PTGESCYP2C9 | |
| SCHEMBL16025939 | 0.86 | PTGS2 (0.76) | PTGS2PTGS1PDPK1PTGESCYP2C9 | |
| SCHEMBL16025850 | 0.85 | PTGS2 (0.72) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL27535162 | 0.84 | PTGS2 (0.77) | PTGS2PTGS1PDPK1PTGESCYP2C9 | |
| SCHEMBL6430302 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1PDPK1PTGESCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190038756-A1 | COMPOSITIONS INCLUDING BENZENESULFONAMIDE-CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, SILK FIBROIN, AND A GELLING AGENT AND USES THEREOF | COCOON BIOTECH INC. | 2019-02-07 | — | — | US | disclosed |
| EP-3413889-A1 | COMPOSITIONS INCLUDING BENZENESULFONAMIDE-CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS SILK FIBROIN AND A GELLING AGENT AND USES THEREOF | Cocoon Biotech Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139684-A1 | COMPOSITIONS INCLUDING BENZENESULFONAMIDE-CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS SILK FIBROIN AND A GELLING AGENT AND USES THEREOF | COCOON BIOTECH INC. (US) | 2017-08-17 | — | — | WO | disclosed |
| US-RE44048-E1 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder | G.D. SEARLE LLC (US) | 2013-03-05 | — | — | US | disclosed |
| CN-101242875-A | Ophthalmic composition containing mucoadhesive polysaccharides capable of promoting corneal re-epithelialization | OPOCRIN SPA (IT) | 2008-08-13 | — | — | CN | disclosed |
| EP-1682143-A2 | COMBINATIONS COMPRISING AN HSP90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA | Pharmacia Corporation (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20060142368-A1 | Compounds and methods for inducing apoptosis in proliferating cells | MRDC | 2006-06-29 | — | — | US | disclosed |
| US-7026346-B2 | Compounds and methods for inducing apoptosis in proliferating cells | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1499597-A4 | COMPOUNDS AND METHODS FOR INDUCING APOPTOSIS IN PROLIFERATING CELLS | UNIV OHIO STATE RES FOUND (US) | 2006-01-25 | — | — | EP | disclosed |
| US-6951949-B2 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2005-10-04 | — | — | US | disclosed |
| EP-0854723-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997011704-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1997-04-03 | — | — | WO | disclosed |
| CN-1141630-A | Substituted pyrazolyl benzenesulfonamides for treating inflammation | SEARLE & CO (US) | 1997-01-29 | — | — | CN | disclosed |
| US-5563165-A | PROSTAGLANDIN INHIBITOR; FDA ORANGE BOOK LISTED PATENT FOR CELEBREX | G. D. SEARL & CO. (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0731795-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | disclosed |
| US-5521207-A | Substituted pyrazolyl benzenesulfonamide for the treatment of inflammation | G.D. SEARLE & CO. (US) | 1996-05-28 | — | — | US | disclosed |
| US-5516907-A | ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1996-05-14 | — | — | US | disclosed |
| US-5508426-A | ANTIARTHRITIC AGENT | G. D. SEARLE & CO. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5466823-A | Antiinflammatory agents; FDA Orange book listed patent for Celebrex | G.D. SEARLE & CO. (US) | 1995-11-14 | — | — | US | disclosed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038756-A1 | COMPOSITIONS INCLUDING BENZENESULFONAMIDE-CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, SILK FIBROIN, AND A GELLING AGENT AND USES THEREOF | MB, PTGES, PTGS1 | PTGS2 12/4885PTGS1 3/4885PDPK1 4020/4885 |
| US-20060142368-A1 | Compounds and methods for inducing apoptosis in proliferating cells | MCL1, BRDT, BAD | PTGS2 370/4885PTGS1 303/4885PDPK1 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.